ISRCTN ISRCTN15255286
DOI https://doi.org/10.1186/ISRCTN15255286
Secondary identifying numbers 1
Submission date
08/12/2016
Registration date
08/12/2016
Last edited
14/08/2019
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
Sudden cardiac arrest (SCA) is a serious medical condition in which the heart suddenly stops beating. It is commonly caused by cardiac arrhythmia (heart rhythm disorder) and is the most common cause of death in the developed world. These heart rhythm disorders are caused by complex interactions between various factors such as inherited factors, lifestyle factors and environmental factors. A SCA is lethal within minutes if left unteated, in particular, rapid defibrillation (a shock to the chest to get the heart pumping again) and resuscitation are crucial to increase chances of survival. This, along with prevention strategies are the best ways for prventing death from SCA. The difficulty with these strategies lies in the fact that SCA generally occurs unexpectedly and out-of-hospital. Because of this, it is usually very difficult to obtain clear information about all the factors that have caused the SCA in that particular person. The ARREST registry is designed to resolve these difficulties by improving understanding of the causes of SCA in the community and by evaluating the most effective treatments of SCA. To achieve this aim, the ARREST registry includes all out-of-hospital SCA cases in a particular region of the Netherlands, collecting information of the factors that may underlie SCA occurrence, along with detailed data on the ways in which resuscitation was performed. The aim of this study is to evaluate the ARREST registry and its use in understanding the causes of SCA and the best treatments.

Who can participate?
All individuals in the ARREST region (North-Holland province of the Netherlands) who suffer out-of-hospital SCA.

What does the study involve?
Information about sudden cardiac arrest (SCA) patients is collected from the emergency medical services, hospital, general practitioner, public pharmacy, and public registries; DNA is collected from residual material taken for the sake of patient care (e.g., blood samples). Patients are enrolled in this study when they suffer SCA. They cannot provide informed consent prior to enrolment, because occurrence of SCA is presently unpredictable. Informed consent can also not be obtained during SCA, because SCA is a medical emergency, in which the patients are unconscious. Therefore, informed consent can only be obtained afterwards. Survivors of SCA are therefore contacted after they have recovered sufficiently to have regained their ability to make an informed decision to provide written consent to participate in this study. If they decide not to participate, the patient is withdrawn from the study and DNA samples will be destroyed.

What are the possible benefits and risks of participating?
A possible benefit is that this study improves the ability to prevent SCA (SCA victims are at increased risk of suffering SCA again), and to develop more effective treatments for out-of-hospital SCA. There are no risks involved with participating.

Where is the study run from
Department of Cardiology, Heart Center, Academic Medical Center (Netherlands)

When is study starting and how long is it expected to run for?
June 2005 to December 2031

Who is funding the study?
1. European Commission: Horizon 2020 (Belgium)
2. Netherlands CardioVascular Research Initiative (Netherlands)
3. Netherlands Organization for Scientific Research (Netherlands)
4. Dutch Medicines Evaluation Board (Netherlands)
5. Dutch Heart Foundation (Netherlands)
6. Zoll Medical (Netherlands)
7. Cardiac Science (USA)
8. ZonMW (Netherlands)
9. Laerdal Foundation (Netherlands)

Who is the main contact?
1. Dr Hanno Tan (scientific)
2. Dr Marieke Blom (scientific)

Contact information

Dr Hanno Tan
Scientific

Academisch Medisch Centrum
Meibergdreef 9
Amsterdam
1105 AZ
Netherlands

ORCiD logoORCID ID 0000-0002-7905-5818
Dr Marieke Blom
Scientific

Academisch Medisch Centrum
Meibergdreef 9
Amsterdam
1105 AZ
Netherlands

ORCiD logoORCID ID 0000-0002-8088-1105

Study information

Study designObservational prospective cohort study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Community
Study typeOther
Participant information sheet Not available in web format, please use contact details to request a participant information sheet.
Scientific titleARREST registry: AmsteRdam REsuscitation STudies
Study acronymARREST
Study hypothesis1. Sudden cardiac arrest may be prevented by understanding the interactions between the underlying causative factors
2. Sudden cardiac arrest may be better treated by designing more effective out-of-hospital treatment strategies
Ethics approval(s)1. Medical Ethics Committee Academic Medical Center Amsterdam, 28/03/2007, ref: 07.17.0430
2. Biobank Ethics Committee Academic Medical Center Amsterdam, 27/03/2016, ref: 2015_125
ConditionOut-of-hospital cardiac arrest
InterventionNo interventions will be conducted specifically for the sake of this study. Data of the sudden cardiac arrest (SCA) patients will be collected from the emergency medical services, hospital, general practitioner, public pharmacy, and public registries; DNA will be collected from residual material taken for the sake of patient care (e.g., blood samples).

Patients are enrolled in this study when they suffer SCA. They cannot provide informed consent prior to enrolment, because occurrence of SCA is presently unpredictable. Informed consent can also not be obtained during SCA, because SCA is a medical emergency, in which the patients are unconscious. Therefore, informed consent can only be obtained afterwards. Survivors of SCA will therefore be contacted after they have recovered sufficiently to have regained their ability to make an informed decision to provide written consent to participate in this study. If they decide not to participate, the patient will be withdrawn from the study and DNA samples will be destroyed.
Intervention typeOther
Primary outcome measure1. Causes of SCA are measured by studying genetic material, medication history from the patient's pharmacist, medical data retrieved from the patient's general practitioner and/or treating hospital and (social) environmental data retrieved from the national statistics agency.
2. Survival after out-of-hospital SCA, measured at hospital discharge using hospital records, and 30-day survival using basic civic registry
Secondary outcome measuresQuality of life after surviving SCA is measured using score on Cerebral Performance Category at hospital discharge.
Overall study start date01/01/2005
Overall study end date01/01/2031

Eligibility

Participant type(s)Patient
Age groupAll
SexBoth
Target number of participants15,000
Participant inclusion criteriaAll patients who suffer out-of-hospital cardiac arrest in the ARREST study region
Participant exclusion criteriaThere are no exclusion criteria
Recruitment start date01/06/2005
Recruitment end date01/01/2030

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Academic Medical Center
Department of Cardiology
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands
Amsterdam
1105 AZ
Netherlands

Sponsor information

Academic Medical Center (AMC)
Research organisation

Meibergdreef 9
Amsterdam
1105 AZ
Netherlands

Phone +31-20-5664678
Email arrest@amc.uva.nl
ROR logo "ROR" https://ror.org/03t4gr691

Funders

Funder type

Government

European Commission: Horizon 2020

No information available

Netherlands CardioVascular Research Initiative: The Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development, and the Royal Netherlands Academy of Sciences (PREDICT project)

No information available

Netherlands Organization for Scientific Research (NWO)

No information available

Dutch Medicines Evaluation Board (MEB/CBG)

No information available

BBMRI-NL

No information available

Dutch Heart Foundation

No information available

Physio-Control Inc

No information available

Zoll Medical

No information available

Cardiac Science

No information available

ZonMW

No information available

Laerdal Foundation

No information available

Results and Publications

Intention to publish date08/12/2017
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planPlanned publication in a high-impact peer reviewed journal, yearly throughout the study.
IPD sharing planNot expected to be available, because of privacy considerations: risk of exposing patient identifying information. Data are held at Academic Medical Center, Amsterdam.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 06/08/2014 14/08/2019 Yes No

Editorial Notes

14/08/2019: Publication reference added.
23/07/2019: Internal review.